DK3565550T3 - Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan - Google Patents
Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan Download PDFInfo
- Publication number
- DK3565550T3 DK3565550T3 DK18736278.5T DK18736278T DK3565550T3 DK 3565550 T3 DK3565550 T3 DK 3565550T3 DK 18736278 T DK18736278 T DK 18736278T DK 3565550 T3 DK3565550 T3 DK 3565550T3
- Authority
- DK
- Denmark
- Prior art keywords
- rizatriptane
- pharmaceutical compositions
- compositions including
- including meloxicam
- meloxicam
- Prior art date
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title 1
- 229960001929 meloxicam Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762442136P | 2017-01-04 | 2017-01-04 | |
US201762504105P | 2017-05-10 | 2017-05-10 | |
US201762536466P | 2017-07-25 | 2017-07-25 | |
PCT/US2018/012433 WO2018129220A1 (en) | 2017-01-04 | 2018-01-04 | Pharmaceutical compositions comprising meloxicam |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3565550T3 true DK3565550T3 (da) | 2021-01-18 |
Family
ID=62791365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18736278.5T DK3565550T3 (da) | 2017-01-04 | 2018-01-04 | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan |
Country Status (20)
Country | Link |
---|---|
US (4) | US10137131B2 (da) |
EP (2) | EP3565550B1 (da) |
JP (3) | JP6870867B2 (da) |
KR (4) | KR102627411B1 (da) |
CN (1) | CN110621314A (da) |
AU (4) | AU2018205790B2 (da) |
CA (2) | CA3121746A1 (da) |
CO (1) | CO2019008364A2 (da) |
CY (1) | CY1123820T1 (da) |
DK (1) | DK3565550T3 (da) |
ES (1) | ES2845566T3 (da) |
HR (1) | HRP20210034T1 (da) |
HU (1) | HUE052749T2 (da) |
LT (1) | LT3565550T (da) |
MX (2) | MX2019008127A (da) |
PL (1) | PL3565550T3 (da) |
PT (1) | PT3565550T (da) |
RS (1) | RS61346B1 (da) |
SI (1) | SI3565550T1 (da) |
WO (1) | WO2018129220A1 (da) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10512692B2 (en) | 2015-02-10 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11602563B2 (en) | 2015-02-10 | 2023-03-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10695429B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10653777B2 (en) | 2015-02-10 | 2020-05-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10537642B1 (en) | 2015-02-10 | 2020-01-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11738085B2 (en) | 2015-02-10 | 2023-08-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10821181B2 (en) | 2015-02-10 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10722583B2 (en) | 2015-02-10 | 2020-07-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11013805B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10702602B2 (en) | 2015-02-10 | 2020-07-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11013806B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11045549B2 (en) | 2015-02-10 | 2021-06-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11110173B2 (en) | 2015-02-10 | 2021-09-07 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
US10058614B2 (en) | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10517950B1 (en) | 2015-02-10 | 2019-12-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10758618B2 (en) | 2015-02-10 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10933136B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11607456B2 (en) | 2015-02-10 | 2023-03-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10799588B2 (en) | 2015-02-10 | 2020-10-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10933137B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10729774B1 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10780165B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10780166B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10729773B2 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10532101B1 (en) | 2015-02-10 | 2020-01-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10695430B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10940153B2 (en) | 2017-01-04 | 2021-03-09 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10583144B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11433078B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10894053B2 (en) | 2017-01-04 | 2021-01-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10471014B2 (en) | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10729696B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11471465B2 (en) | 2017-01-04 | 2022-10-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11433079B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11806354B2 (en) | 2017-01-04 | 2023-11-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11266657B2 (en) | 2017-01-04 | 2022-03-08 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10583088B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10729697B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11801250B2 (en) | 2017-01-04 | 2023-10-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10561664B1 (en) | 2017-01-04 | 2020-02-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10821182B2 (en) | 2017-06-29 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10905693B2 (en) | 2017-01-04 | 2021-02-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
SI3565550T1 (sl) | 2017-01-04 | 2021-04-30 | Axsome Therapeutics, Inc. | Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan |
US11207327B2 (en) | 2017-01-04 | 2021-12-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11617755B2 (en) | 2017-01-04 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
KR20240094040A (ko) * | 2017-05-10 | 2024-06-24 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학적 조성물 |
US11712441B2 (en) | 2017-06-29 | 2023-08-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10987358B2 (en) | 2017-06-29 | 2021-04-27 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10688102B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Combination treatment for migraine and other pain |
US11510927B2 (en) | 2017-06-29 | 2022-11-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10688185B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10512693B2 (en) | 2017-06-29 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11759522B2 (en) | 2017-06-29 | 2023-09-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10758617B2 (en) | 2017-06-29 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11865117B2 (en) | 2017-06-29 | 2024-01-09 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
US10918722B2 (en) | 2017-06-29 | 2021-02-16 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11617756B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11219626B2 (en) | 2017-06-29 | 2022-01-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11185550B2 (en) | 2017-06-29 | 2021-11-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
WO2020069138A1 (en) * | 2018-09-28 | 2020-04-02 | Axsome Therapeutics, Inc. | Dosage forms comprising active pharmaceutical ingredients |
CN109111469A (zh) * | 2018-10-09 | 2019-01-01 | 中国药科大学 | 一种含氯诺昔康的共无定形复合物 |
SG11202107926XA (en) * | 2019-02-06 | 2021-08-30 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
US20240058354A1 (en) * | 2020-04-06 | 2024-02-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
JP2023520574A (ja) * | 2020-04-06 | 2023-05-17 | アクスサム セラピューティクス インコーポレイテッド | メロキシカムを含む医薬組成物 |
US12128052B2 (en) | 2020-05-28 | 2024-10-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
WO2022122122A1 (en) | 2020-12-08 | 2022-06-16 | Symrise Ag | Medicament for fighting inflammatory conditions of human skin (i) |
US20230355637A1 (en) * | 2020-12-31 | 2023-11-09 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
WO2022147155A1 (en) * | 2020-12-31 | 2022-07-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US12005118B2 (en) | 2022-05-19 | 2024-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284269A (en) | 1993-06-28 | 1994-02-08 | Petrie Jack G | Space saving double seal |
AU3343295A (en) | 1994-08-12 | 1996-03-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazopyridine salt |
CA2197298C (en) | 1994-08-13 | 1999-10-19 | Jong Wook Lee | Novel pyrimidine derivatives and processes for the preparation thereof |
US5872145A (en) | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US6077539A (en) | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
KR100231723B1 (ko) | 1996-12-28 | 1999-11-15 | 김영환 | 플래쉬 메모리 장치 |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
JP2001513563A (ja) | 1997-08-27 | 2001-09-04 | ヘキサル アーゲー | 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物 |
ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
SE9804314D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New pharmaceutical formulation |
UA70357C2 (uk) | 1999-03-26 | 2004-10-15 | Позен Інк. | Фармацевтична композиція дигідроерготаміну (варіанти), спосіб лікування пацієнта з мігреневим головним болем (варіанти), терапевтична упаковка (варіанти) та спосіб її виготовлення (варіанти) |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
EP1411900B2 (en) | 2001-06-01 | 2013-12-04 | Pozen, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs |
MXPA05006954A (es) | 2002-12-26 | 2005-09-22 | Pozen Inc | Formas de dosificacion de capas multiples que contienen nsaids y triptanos. |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
CA2554271A1 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
EP1744757A4 (en) | 2004-05-04 | 2009-04-22 | Equitech Corp | IMPROVED ENHANCED COMPOSITION |
JP4617774B2 (ja) * | 2004-08-26 | 2011-01-26 | コニカミノルタホールディングス株式会社 | カラートナー及びカラーフィルター |
WO2006052921A2 (en) | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
US9265732B2 (en) | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
US20070281927A1 (en) | 2006-06-06 | 2007-12-06 | Shanthakumar Tyavanagimatt | Anti-inflammatory and analgesic compositions and related methods |
WO2008006216A1 (en) | 2006-07-14 | 2008-01-17 | Mistral Pharma, Inc. | Anti-inflammatory and cytoprotectant chronotherapy |
AU2007310949A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
WO2009094155A1 (en) | 2008-01-22 | 2009-07-30 | Thar Pharmaceuticals | In vivo studies of crystalline forms of meloxicam |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
KR101912709B1 (ko) | 2009-05-13 | 2018-10-30 | 사이덱스 파마슈티칼스, 인크. | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 |
MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
DE102010052847A1 (de) | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
CN102526058A (zh) | 2010-12-28 | 2012-07-04 | 秦引林 | 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物 |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
WO2014161131A1 (en) | 2013-04-01 | 2014-10-09 | Arissa Pharma | PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS |
US20170216305A1 (en) | 2014-09-29 | 2017-08-03 | Arissa Pharma Ltd. | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain |
US9821075B2 (en) * | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10058614B2 (en) | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
NZ734233A (en) | 2015-02-10 | 2018-05-25 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
SI3565550T1 (sl) | 2017-01-04 | 2021-04-30 | Axsome Therapeutics, Inc. | Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan |
US10471014B2 (en) | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10583088B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
KR102209773B1 (ko) * | 2017-05-29 | 2021-01-28 | 주식회사 엘지화학 | 배터리 모듈 |
-
2018
- 2018-01-04 SI SI201830182T patent/SI3565550T1/sl unknown
- 2018-01-04 CN CN201880015899.0A patent/CN110621314A/zh active Pending
- 2018-01-04 KR KR1020237002573A patent/KR102627411B1/ko active IP Right Grant
- 2018-01-04 EP EP18736278.5A patent/EP3565550B1/en active Active
- 2018-01-04 CA CA3121746A patent/CA3121746A1/en active Pending
- 2018-01-04 AU AU2018205790A patent/AU2018205790B2/en active Active
- 2018-01-04 JP JP2019536590A patent/JP6870867B2/ja active Active
- 2018-01-04 EP EP20200408.1A patent/EP3789016A1/en active Pending
- 2018-01-04 ES ES18736278T patent/ES2845566T3/es active Active
- 2018-01-04 LT LTEP18736278.5T patent/LT3565550T/lt unknown
- 2018-01-04 DK DK18736278.5T patent/DK3565550T3/da active
- 2018-01-04 RS RS20201580A patent/RS61346B1/sr unknown
- 2018-01-04 KR KR1020217026433A patent/KR102493541B1/ko active IP Right Grant
- 2018-01-04 KR KR1020247001720A patent/KR20240013848A/ko not_active Application Discontinuation
- 2018-01-04 HU HUE18736278A patent/HUE052749T2/hu unknown
- 2018-01-04 MX MX2019008127A patent/MX2019008127A/es unknown
- 2018-01-04 CA CA3049229A patent/CA3049229C/en active Active
- 2018-01-04 WO PCT/US2018/012433 patent/WO2018129220A1/en active Application Filing
- 2018-01-04 PT PT187362785T patent/PT3565550T/pt unknown
- 2018-01-04 PL PL18736278T patent/PL3565550T3/pl unknown
- 2018-01-04 KR KR1020197022825A patent/KR20190122659A/ko not_active IP Right Cessation
- 2018-03-26 US US15/936,176 patent/US10137131B2/en active Active
- 2018-05-10 US US15/976,800 patent/US10471068B2/en active Active
- 2018-11-05 US US16/181,086 patent/US10265324B2/en active Active
-
2019
- 2019-04-03 US US16/374,081 patent/US10471069B2/en active Active
- 2019-07-04 MX MX2021014509A patent/MX2021014509A/es unknown
- 2019-07-30 CO CONC2019/0008364A patent/CO2019008364A2/es unknown
-
2020
- 2020-10-04 AU AU2020244610A patent/AU2020244610B2/en active Active
-
2021
- 2021-01-08 HR HRP20210034TT patent/HRP20210034T1/hr unknown
- 2021-01-14 CY CY20211100028T patent/CY1123820T1/el unknown
- 2021-04-08 JP JP2021065716A patent/JP2021107413A/ja active Pending
-
2022
- 2022-01-29 AU AU2022200590A patent/AU2022200590B2/en active Active
-
2023
- 2023-08-18 JP JP2023133335A patent/JP7568800B2/ja active Active
-
2024
- 2024-08-14 AU AU2024205772A patent/AU2024205772A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
DK3514153T3 (da) | Pyrimidinforbindelse og farmaceutisk anvendelse deraf | |
DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
DK3634377T3 (da) | Farmaceutisk formulering | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3625224T3 (da) | N-substituerede indolderivater | |
DK3399978T3 (da) | Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf | |
DK3560925T3 (da) | Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
DK3615502T3 (da) | Terapeutiske forbindelser og fremgangsmåder | |
MA49837A (fr) | Compositions pharmaceutiques | |
DK3275453T3 (da) | Farmaceutisk sammensætning med silibinin og ve | |
DK3672948T3 (da) | Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser | |
DK3583943T3 (da) | Farmaceutisk sammensætning | |
DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |